Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.

MLA

Li, Siming, et al. “Phosphorylation of MTOR and S6RP Predicts the Efficacy of Everolimus in Patients with Metastatic Renal Cell Carcinoma.” BMC Cancer, vol. 14, May 2014, p. 376. EBSCOhost, https://doi.org/10.1186/1471-2407-14-376.

APA

Li, S., Kong, Y., Si, L., Chi, Z., Cui, C., Sheng, X., & Guo, J. (2014). Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer, 14, 376. https://doi.org/10.1186/1471-2407-14-376

Chicago

Li, Siming, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, and Jun Guo. 2014. “Phosphorylation of MTOR and S6RP Predicts the Efficacy of Everolimus in Patients with Metastatic Renal Cell Carcinoma.” BMC Cancer 14 (May): 376. doi:10.1186/1471-2407-14-376.